KBC Group
ANIP icon

KBC Group’s ANI Pharmaceuticals ANIP Stock Holding History

KBC Group’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$81K Buy
978
+610
+166% +$48.9K ﹤0.01% 1522
2026
Q1 		$28K Buy
+368
New +$28.7K ﹤0.01% 1806
2025
Q2 		– Sell
-1,273
Closed -$85K – 1721
2025
Q1 		$85K Hold
1,273
– – ﹤0.01% 1575
2024
Q4 		$70K Buy
1,273
+600
+89% +$34.4K ﹤0.01% 1729
2024
Q3 		$40K Hold
673
– – ﹤0.01% 1779
2024
Q2 		$43K Hold
673
– – ﹤0.01% 1696
2024
Q1 		$47K Hold
673
– – ﹤0.01% 1589
2023
Q4 		$37K Hold
673
– – ﹤0.01% 1702
2023
Q3 		$39K Sell
673
-408
-38% -$23.5K ﹤0.01% 1635
2023
Q2 		$58K Hold
1,081
– – ﹤0.01% 1327
2023
Q1 		$43K Hold
1,081
– – ﹤0.01% 1412
2022
Q4 		$43K Hold
1,081
– – ﹤0.01% 1426
2022
Q3 		$35K Hold
1,081
– – ﹤0.01% 1458
2022
Q2 		$32K Buy
+1,081
New +$31.2K ﹤0.01% 1491
2020
Q1 		– Sell
-17,006
Closed -$1.05M – 1289
2019
Q4 		$1.05M Hold
17,006
– – 0.01% 882
2019
Q3 		$1.24M Hold
17,006
– – 0.01% 798
2019
Q2 		$1.4M Sell
17,006
-1,290
-7% -$91.7K 0.01% 720
2019
Q1 		$1.29M Sell
18,296
-3,930
-18% -$231K 0.01% 768
2018
Q4 		$1M Sell
22,226
-6,731
-23% -$353K 0.01% 744
2018
Q3 		$1.64M Buy
28,957
+8,598
+42% +$526K 0.01% 756
2018
Q2 		$1.36M Buy
20,359
+4,302
+27% +$269K 0.01% 713
2018
Q1 		$935K Hold
16,057
– – 0.01% 799
2017
Q4 		$1.03M Hold
16,057
– – 0.01% 795
2017
Q3 		$843K Hold
16,057
– – 0.01% 847
2017
Q2 		$751K Buy
16,057
+4,143
+35% +$200K 0.01% 856
2017
Q1 		$590K Buy
11,914
+1,961
+20% +$110K 0.01% 1002
2016
Q4 		$603K Buy
+9,953
New +$609K 0.01% 994

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KBC Group's ANIP Position: Q2 2026 in Review

KBC Group increased its ANI Pharmaceuticals (ANIP) stake by 166% in Q2 2026, buying an estimated $48.9K and bringing the position to 978 shares worth $81K. The position accounts for ﹤0.01% of the portfolio, ranked #1522.

KBC Group first reported a position in ANIP in Q4 2016 and has held it in 27 quarters since. The position peaked at $1.64M in Q3 2018. 308 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • KBC Group held 978 shares of ANI Pharmaceuticals worth $81K as of Q2 2026.
  • KBC Group bought 610 ANI Pharmaceuticals shares in Q2 2026, an estimated $48.9K.
  • ANI Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1522 holding.
  • KBC Group first reported a position in ANI Pharmaceuticals in Q4 2016 and has held it in 27 quarters since.
  • KBC Group's ANI Pharmaceuticals position peaked at $1.64M in Q3 2018.
  • 308 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.